Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

OBJECTIVE: We evaluated the metabolic effects and tolerability of GFT505, a novel dual peroxisome proliferator–activated receptor α/δ agonist, in abdominally obese patients with either combined dyslipidemia or prediabetes. RESEARCH DESIGN AND METHODS: The S1 study was conducted in 94 patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cariou, Bertrand, Zaïr, Yassine, Staels, Bart, Bruckert, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161281/
https://www.ncbi.nlm.nih.gov/pubmed/21816979
http://dx.doi.org/10.2337/dc11-0093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161281/
https://www.ncbi.nlm.nih.gov/pubmed/21816979
http://dx.doi.org/10.2337/dc11-0093

Ejemplares similares